Peritoneal fluid exosomes as potential biomarkers for endometriosis: mind and bridge the gap between innovation and validation/development into benefit for patients


Like Comment
Related Content

Volume 113, Issue 2, Pages 326–327


Arne Vanhie, M.D.a,b, Carla Tomassetti, M.D., Ph.D.a,b, Thomas M. D’Hooghe, M.D., Ph.D.a,c,d


Reflections on "Characterization of exosomes in peritoneal fluid of endometriosis patients" by Nazri et al.

Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 


Go to the profile of Thomas T Tapmeier
over 1 year ago

In general, it is worth remembering that biomedical science demands a lot of patience from scientists, funders and the patients as the prospective beneficiaries of the research alike: The task at hand incredibly difficult, as we are trying to reprogram a computer, as it were, that was not built by ourselves, with only a rudimentary understanding of the hardware and software involved.

As mentioned in the editorial, during the past few decades the endometriosis field has seen investigations into prostaglandins, cytokines, stem cells and genetics, and, as the most recent approach, systems biology; and while none of these have so far delivered new drugs against endometriosis, all of these have contributed to our knowledge of the condition. Exosome biology will no doubt be part of this line, too.

While the limitations of our study were painfully obvious to us with regards to sample size and availability, the potential of isolating particles with a cargo indicative of ongoing processes within the cell of origin directly from patient samples needed to be addressed.

A direct translation into the clinic may still be far off but we hope our proof-of-concept study will help to eventually bridge the gap between scientific innovation and clinical benefit to endometriosis patients.